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AbstrAct:
The Pim kinases are weak oncogenes. However, when co-expressed with a strong 
oncogene, such as c-Myc, Pim kinases potentiate the oncogenic effect resulting in 
an acceleration of tumorigenesis. In this study we show that the least studied Pim 
kinase, Pim-3, is encoded by a gene directly regulated by c-Myc via binding to one 
of the conserved E-boxes within the Pim3 gene. Accordingly, lymphomas arising 
in Myc-transgenic mice and Burkitt lymphoma cell lines exhibit elevated levels of 
Pim-3. Interestingly, inhibition of Pim kinases by a novel pan-Pim kinase inhibitor, 
Pimi, in Myc-induced lymphoma results in cell death that appears independent of 
caspases. The data indicate that Pim kinase inhibition could be a viable treatment 
strategy in certain human lymphomas that rely on Pim-3 kinase expression.
IntroductIon
Tumorigenesis is a multistep process where several 
acquired genetic alterations, or hallmarks, occur leading to 
transformation of a cell [1]. c-Myc is a transcription factor 
with more than 1000 target genes (www.myccancergene.
org), many of which directly impinge on the hallmarks 
of cancer. Therefore, Myc expression is often selected 
for during various steps in the genesis of many types of 
human cancer. To avoid transformation, normal cells can 
respond to Myc overexpression by undergoing apoptosis 
or senescence [2, 3]. Thus, for Myc overexpression 
to drive transformation additional genetic alterations 
affecting apoptotic signaling are required [4], thereby 
allowing the state of genomic instability that facilitates 
the required accumulation of mutations. 
The Pim kinase family is a group of three serine/
threonine kinases encoded by genes that were identified 
as hotspots for proviral integration of Moloney murine 
leukemia virus (Pim) in retrovirus-induced lymphomas 
[5]. The three kinases, Pim-1, Pim-2 and Pim-3, are 
considered weakly oncogenic when expressed as 
transgenes [6-8]. However, when co-expressed with Myc 
they strongly accelerate Myc-driven lymphomagenesis 
[6, 9-11]. The Pim kinase genes are located on different 
chromosomes but they encode proteins with similar sizes 
and with a high degree of homology [12]. 
The Pim kinases phosphorylate a wide variety 
of cellular targets involved in regulating the cell cycle, 
including cyclin-dependent kinase inhibitors p21 and 
p27 [13-15], cell cycle proteins such as CDC25A and 
CDC25C [16, 17]and suppressors of cytokine signaling 
SOCS1 and SOCS3 [18, 19]. Moreover Pim kinases also 
phosphorylate proteins involved in translation such as 
eIF4B [20] and 4EBP1 [21], pro-apoptotic Bcl-2 family 
member Bad [21-24] and transcriptional regulators such 
as Myc [25], Myb [26], RUNX1 and RUNX3 [27]. 
Recently it was shown that Pim-1 can bind the Myc-Max 
complex and so get recruited to E-boxes from where 
Pim-1 can phosphorylate serine 10 on histone H3 [28]. 
This phosphorylation regulates up to 20% of the Myc 
transcriptional targets, some of which are needed for Myc 
driven transformation. It is not known whether all of the 
above-described functions represent separable functions Oncotarget 2011; 2:  448 - 460 449 www.impactjournals.com/oncotarget
of  the  different  Pim  family  members  or  if  significant 
redundancies exist. Nevertheless, single knockout mice 
do not have any overt phenotype whereas triple Pim1-/-
;Pim2-/-;Pim3-/- knockout mice are smaller and exhibit a 
small defect in lymphomcyte stimulation capacity [12]. 
Despite the strong genetic links between Myc 
and Pim kinases emanating from experimental models 
of cancer, it is not clearly established whether or not 
activation of Pim kinases occurs spontaneously in Myc-
induced lymphomas. To address this we analyzed B-cell 
tumors that arose in λ-Myc transgenic mice [29], which 
express c-Myc under the control of the immunoglobulin 
Figure 1: Pim-3 expression is elevated in mouse and human lymphoma tissue. (A) Quantitative reverse transcription PCR 
(qRT-PCR) analysis of Pim kinase expression in B cells from wildtype and precancerous λ-Myc transgenic mice (λ), and in lymphomas 
harvested from λ-Myc transgenic mice. Pim kinase levels were normalized to that of ubiquitin (Ub) (B) Western blot analysis of Pim-3 
kinase (using an antibody from Cell signaling) in same material as analyzed by qRT-PCR. (C) qRT-PCR analysis of Pim-kinase expression 
in cell lines established from λ-Myc and Eμ-Myc transgenic mice. (D) qRT-PCR analysis of Pim-kinase expression in Human Burkitt 
lymphoma cell lines. The expression levels are relative to that of one of the cell lines, DG75. (E) Immunohistochemistry analysis of Pim-3 
expression in various lymphomas from patients. The antibody was from Abcam.
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Figure 2: the Pim3 gene has evolutionary conserved E-boxes, which mediate Myc-regulated transcription. (A) 
Schematic representation of mouse and human Pim3 loci, which contain two evolutionarily conserved E-boxes (CACGTG). (B) NIH 
3T3 fibroblasts carrying a MycER construct were treated with the estrogen receptor (ER) agonist 4-hydroxytamoxifen (4-HT) with or 
without the translation inhibitor cycloheximide (CHX) for 4 h and were then harvested for qRT-PCR analysis of Pim expression. Srm, 
a Myc target gene with five E-boxes, was used as a positive control. (C) Chromatin immunoprecipitation (ChIP) assay was run on λ820 
cells using a Myc antibody to immunoprecipitate the E-box regions. Immunoprecipitated chromatin was subsequently analyzed by qPCR 
utilizing primers directed against E-box regions of the Myc target genes Srm and Odc but also against the E-box1 in the Pim3 locus. As 
a negative control primers designed not to recognize the Pim3 gene (Pim3-ctrl) were used. Percent total chromatin immunoprecipitated 
was calculated using the equation % total = 2 (Ct input - Ct ChIP) x % input and was presented as “Relative fold increase” calculated accordingly, 
% total sample / % total negative control. The negative control value was generated by immunoprecipitation using normal rabbit IgG. 
Shown is one of two independent experiments yielding similar results. (D) The human BL cell line P493-6 carrying a tetracycline (tet-
off) regulatable system for Myc expression was cultured with 0.1μg/ml tetracycline (tet) or without tet for 8 hours, after which cells were 
harvested for qRT-PCR analysis of Pim and Myc transcripts (E) P493-6 cells from the same experiment were also harvested for western blot 
analysis of Pim-3 and Myc protein expression. (F) P493-6 cells were cultured with tetracycline for 72 hours and then divided into two sub-
cultures, one with tetracycline (myc off) and one without (myc on), and were cultured for another 8 hours before being harvested for ChIP 
analysis. Chromatin was immunoprecipitated using a Myc antibody and the qPCR was run with primers directed against the PIM3 E-box1, 
primers not recognizing the PIM3 gene as negative controls, and primers against CCND2 as a positive control. Percent total chromatin 
immunoprecipitated was calculated as described above. Data were presented as “Fold increase (%total – tet / %total+tet)”. Shown is one of 
two independent experiments yielding similar results.
Pim3 mouse gene NC 00081
7533 bp
CDS E-box 1 E-box 2 mRNA
Pim-3 human gene NC 000022
7578 bp
CDS E-box 1 E-box 2 mRNA
0
1
2
3
4
5
6
7
8
9
Srm Odc Pim3-Ebox1 Pim3-ctrl
A B
C D
0
1
2
3
4
5
6
7
8
9
10
hMyc Pim1 Pim2 Pim3
P4936 (Myc
off)
P4936 (Myc
on 8hr)
*
E F
Myc
Pim-3
Actin
Tet       +       -
0
2
4
6
8
10
12
F
o
l
d
 
i
n
c
r
e
a
s
e
 
(
%
t
o
t
a
l
-
t
e
t
/
%
t
o
t
a
l
+
t
e
t
)
0
2
4
6
8
10
12
14
EtOH CHX-EtOH 4HT 4HT-CHX
Pim1
Pim2
Pim3
Srm
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
t
o
 
U
b
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
t
o
 
U
b
R
e
l
a
t
i
v
e
 
C
h
I
P
a
m
o
u
n
tOncotarget 2011; 2:  448 - 460 451 www.impactjournals.com/oncotarget
l enhancer. To our surprise we find that the most highly 
expressed Pim kinase in these lymphomas is Pim-
3, and that Pim3 is a Myc target gene. These data may 
partly explain why proviral activation of Pim1 and 
Pim2 in Eµ-Myc mice occurs most frequently – Pim3 
is already activated by Myc. Importantly, we also show 
that inhibition of Pim kinases induces cell death of Myc-
induced lymphomas.
rEsults
Pim-3 kinase protein levels are elevated in Myc 
over expressing tumors
Although considered weak oncogenes, all Pim 
kinase family members have been shown to strongly 
potentiate Myc driven tumorigenesis as proviral insertion 
targets or transgenes [6, 9-11]. Although these landmark 
studies established a genetic link between Myc and Pim 
kinases, they did not address whether this synergy could 
be established spontaneously in a reciprocal manner. 
To partly address this we analyzed B-cell tumors from 
λ-Myc transgenic mice for Pim kinase mRNA expression 
levels. Quantitative reverse transcriptase PCR (qRT-PCR) 
showed that elevated RNA levels of Pim1 and Pim2 could 
be observed in some tumors but that Pim3 was the only 
Pim  kinase  family  member  with  significantly  elevated 
mRNA levels in all tumors as compared to wildtype B 
cells (Figure 1A). Interestingly, elevated Pim3 mRNA and 
Pim-3 protein were seen not only in tumors but also in B 
cells harvested from 4-6 week old precancerous mice with 
no signs of lymphoma (Figure 1A and 1 B). Moreover, 
tumor  cell  lines  established  from  λ-Myc and Eµ-Myc 
transgenic mouse B cell tumors still exhibited elevated 
mRNA levels of Pim3, suggesting the importance of 
maintaining expression even in conditions of surplus 
growth factors (Figure 1C). To analyze which of the 
Pim kinases were expressed in human lymphomas, we 
analyzed a set of human Burkitt lymphoma (BL) cell lines 
by qRT-PCR. When Pim kinase expression in the human 
BL cell line DG75 was set to 1, it appeared as if Pim1 
and Pim2 mRNA is elevated in all the BL cells (Figure 
1D). However, when analyzing the Ct values it became 
obvious that Pim3 was the more abundant Pim transcript 
because a signal was obtained at cycle 21, as opposed to 
cycle 23 or higher for Pim1 and Pim2 mRNAs. Moreover, 
immunohistochemistry analysis of Pim-3 expression 
in mantle cell lymphoma (MCL), follicular lymphoma 
(FL), diffuse large cell B-  cell lymphoma (DLCBL) and 
BL showed that BL is the lymphoma-type that exhibits 
the highest Pim-3 expression (Figure 1E). Taken together, 
the data indicate that Pim-3 is the main Pim kinase 
overexpressed in Myc-induced lymphomas from mice and 
patients whereas Pim-1 and Pim-2 are more sporadically 
overexpressed. 
Pim3 is a direct Myc transcriptional target
Myc transcription is mediated through E box 
sequences, most often CACGTG [30-37]. To investigate 
if the high levels of Pim-3 in Myc-expressing cells and 
tumors were due to a direct induction of transcription, we 
first analyzed the nucleotide sequence of the Pim3 locus 
and found that it contains two potential E-boxes, which 
were conserved in mice and man (Figure 2A). We then 
infected NIH3T3 fibroblasts with a retrovirus expressing 
Myc-ER, an inducible form of Myc that can be activated 
by adding the estrogen analog 4-hydroxytamoxifen (4-HT) 
to the culture medium. Addition of 4-HT, with or without 
the translation inhibitor cycloheximide, showed that the 
mRNA of the direct Myc target Srm could be induced 
2-fold even when translation was inhibited, as could Pim3 
mRNA (Figure 2B). Because Pim3 also was induced by 
cycloheximide, which complicates interpretation of these 
types of experiments, we analyzed whether Myc binds 
the E-boxes of the Pim3 locus by performing chromatin 
immunoprecipitation assay (ChIP) on formaldehyde 
cross-linked DNA from a λ-Myc transgenic mouse B-cell 
lymphoma cell line, λ820, established in our laboratory 
[38]. Indeed, when ChIP was performed using primers 
designed to flank E-box 1 of Pim3, the signal obtained 
was comparable to that of the signal obtained with primers 
against Srm and Odc (Figure 2C), two confirmed Myc 
transcriptional targets [39, 40]. Primers against a sequence 
one kb downstream of the Pim3 gene was used as negative 
control, and yielded signals 3-7 times weaker. To assess if 
Myc directly regulates PIM3 in human cells we used the 
P493-6 lymphoma cell line, which has a tetracycline (Tet) 
regulatable Myc cassette, which is silent in the presence of 
tetracycline [41]. P493-6 cells were incubated 72 hours in 
the presence of tetracycline (Myc off) after which they were 
split in two cell culture flasks, one culture with tetracycline 
(Myc off) and one culture without tetracycline (Myc on). 
The two cultures were then incubated for 8 hours, after 
which cells were harvested for mRNA, protein and ChIP 
analysis. We ran a qRT-PCR on mRNA harvested from 
these samples to measure the PIM levels with and without 
Myc expression. In accordance with the mouse results 
expression of Pim-3 kinase, but not Pim-1 or Pim-2, was 
induced by Myc activation at the transcriptional (Figure 
2D) and translational level (Figure 2E). Moreover, ChIP 
experiments performed using a Myc antibody showed that 
the PIM3 E-box 1 was immunoprecipitated from the same 
P493-6 cell preparation, although to a lesser extent than 
the Myc target gene Cyclin D2 (CCND2) [42-44] (Figure 
2F). Taken together, our results confirm that E-box 1 in 
the PIM3 locus is a functional target of Myc-mediated 
transcription in both human and mouse lymphoma cells. Oncotarget 2011; 2:  448 - 460 452 www.impactjournals.com/oncotarget
Figure 3: Inhibition of Pim kinases leads to de-phosphorylation of the pro-apoptotic protein bad on serine 112 and 
induction of cell death. (A) Eμ239 cells were cultured for 4 hours in the presence of the indicated concentrations of DMSO, Pim-ci 
or the Pim inhibitor Pimi, after which cells were harvested for western blot analysis of Bad serine 112 phosphorylation. B) Eμ239 cells 
were cultured in the presence of different concentrations of the indicated drugs and counted using trypan blue dye exclusion. C) Burkitt 
Lymphoma cell lines were cultured in the presence of 10 μM Pimi or DMSO (not shown) for 24 and 48 hours. At each time point aliquots 
of cells were taken for cell counting (by trypan blue dye exclusion) to monitor cell growth. D) At the indicated time points aliquots of 
cells were stained with propidium iodide and scored for the ratio of cells having less than a diploid DNA content (n<2), Sub G1, by FACS 
analysis. E) RNA from Eμ239 cells cultured for 24 hours in the presence of 10 μM Pimi was harvested and analyzed by qRT-PCR for 
expression of the Myc transcriptional target genes, Amd1, Aurkb, Cad, Id2, Shmt1, Shmt2 and Srm. All values were normalized to that of 
the control primers, ubiquitin (Ub) run on the same sample. 
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the Pim kinase inhibitor Pimi hampers cellular 
proliferation and causes a reduction in Myc 
regulated transcripts
Pim kinase expression has been associated with 
poor outcome in several different tumor types [45-
58] and chemoresistance have been seen in tumor cells 
overexpressing the Pim kinases [59-62]. This has inspired 
efforts to inhibit the Pim kinases as a cancer treatment. 
Since the triple knockout Pim kinase mice are viable and 
fertile, this suggests that inhibition of the Pim kinase 
family could be possible without severe side effects 
[12]. To test this notion we obtained a specific pan-Pim 
kinase inhibitor (Compound 14j [63] [A953864.1] or from 
now on Pimi) generated by Abbott Laboratories (Abbott 
Park, IL). This inhibitor exhibits low nanomolar activity 
against Pim-3, Pim-1 and Pim-2 (0.5 nM, 2 nM, 3 nM, 
respectively) and shows high degree of selectivity for 
Pim kinases (personal communication, Dr. Joel Leverson, 
Abbott Laboratories). To investigate if this inhibitor 
hits the expected targets, Pim kinases, and exhibits anti-
proliferative activity in Myc-induced lymphomas, we 
treated the mouse B-cell lymphoma cell lines Eµ239 and 
λ820 with Pimi and Pim-ci, a 1000-fold less potent Pim 
inhibitor from the same chemical series. As seen in Figure 
3A, Western Blot analysis revealed that phosphorylation 
of the pro-apoptotic BH3-only Bcl-2 family member 
Bad on Ser112, which is believed to be a specific Pim 
kinase site, started to become decreased at 10 nM and 
was abolished in cells treated for 8 h with 10 µM Pimi, 
whereas Pim-ci did not affect phosphorylation. Moreover, 
measurement of incorporation of 3H-thymidine following 
48 h of treatment with 10 nM to 10 µM Pimi demonstrated 
an EC50 of 2.6 µM or 6 µM for Eµ239 and λ820 cells, 
respectively (not shown). Since Pim-ci and the vehicle, 
DMSO, did not exert any anti-proliferative effects when 
added in the same relative quantities, we did not calculate 
EC50s for them. 
To gain insight into the anti-proliferative effect of 
Pimi we generated growth curves on B cell lymphoma 
lines from mice and BL patients. Much like what was 
suggested from the 3H-thymidine incorporation assay, 
Eµ239 cells were sensitive to 10 µM Pimi, manifest as 
both slower growth and induction of cell death (Figure 
3B). Surprisingly however, the anti-proliferative effect 
was only observed in a few human BL cell lines and 
growth curves and DNA histograms from FACS analysis 
of propidium iodide-labeled samples of the cell lines 
showed that Pimi was cytotoxic in Akata cells but only 
cytostatic in Daudi and Raji-EBNA6 cells (Figure 3C and 
3D). 
Pim-1 has been reported to facilitate transcriptional 
activation of 20% of Myc transcriptional targets through 
phosphorylation of Serine10 on histone H3 (H3S10) [28]. 
The phosphorylation is mediated by Pim-1 interacting 
with Myc in the transcriptional active Myc-Max dimer, 
thus recruiting Pim-1 to E-boxes of active transcription. 
Since inhibition of Myc signaling in Myc-driven tumors 
can lead to growth arrest, senescence and cell death we 
entertained the idea that the observed effect of Pimi could 
be mediated by inhibition of Myc function. We therefore 
treated the mouse B cell lymphoma cell line Eµ239 with 
10 μM Pimi for 24 hours, harvested mRNA and analyzed 
it using qRT-PCR for the Myc regulated genes Amd1 [39] 
, Aurkb [64], Cad [65], Shmt1, Shmt2 [66] and Srm [39]. 
Interestingly, several of the Myc-regulated target genes 
were down-regulated in Pimi-treated cells compared 
to DMSO controls (Figure 3E). On the other hand, 
expression of the disputed Myc target gene Id2 [67, 68], 
was induced by Pimi.
Pimi treatment induces caspase-3 independent 
cell death
Phosphorylation of Bad by Akt or Pim kinases 
renders this protein inactive as an inducer of apoptotic 
cell death. Since Pimi blocked Bad phosphorylation and 
since we observed cells with a sub-G1 DNA content 
in Pimi-treated cells, we wanted to investigate if the 
cells died by classical caspase-dependent apoptosis. 
Immunofluorescense on cells treated with Pimi for 24 and 
48 hours with antibodies directed against the cleaved form 
of the death effector caspase-3 showed marked increase in 
caspase-3 positive cells in Pimi-treated cells (Figure 4A). 
This was confirmed by FACS analysis on the same cells 
run in parallel. To define which phase of the cell cycle 
Pimi-treated cells died in, we performed a FACS analysis 
of fixed cells labeled with an antibody targeting cleaved 
caspase-3. Co-staining of DNA using 7-aminoactinomycin 
D (7-AAD) enabled us to analyze how caspase-3 positive 
cells were distributed in the cell cycle. As shown in 
Figure 4B, Pimi treatment led to caspase-3 activation in 
the G2/M phase (region 4) and in cells with hyperdiploid 
DNA content (>4n, region 5), suggesting that cells were 
undergoing death because of a problem in mitosis. To test 
whether Pimi-induced cell death is caspase-dependent, 
the pan-caspase inhibitor QVD-OPH was used together 
with  Pimi.  Immunofluorescense  and  FACS  analyses 
showed that QVD-OPH reduces the intensity of caspase-3 
staining but does not block Pimi-activated cell death 
(Figure 4C). These data indicate that inhibition of Pim 
kinases either results in caspase-independent cell death or 
that the caspase inhibition required to block death is not 
pharmacologically achievable.
dIscussIon
Here we show that the Pim3 gene contains conserved Oncotarget 2011; 2:  448 - 460 454 www.impactjournals.com/oncotarget
E-boxes, one of which is bound by Myc, resulting in 
induction of transcription. This is the first time Myc has 
been implicated in regulation of a Pim kinase family 
member and it explains the high levels of Pim-3 found in 
Myc overexpressing mouse B cell lymphomas and human 
BL. It may also explain why Pim1 and Pim2 are more 
frequently trapped by proviral insertions of retroviruses 
in Myc-transgenic mice and why these two genes need to 
be deleted in order to see selection for Pim3 trapping [9]. 
This in turn indicates that Pim-1 and Pim-2 kinases have 
non-redundant functions when expressed at normal levels 
but that they can be replaced by massive overexpression 
of Pim-3. Taken together these data indicate that the 
best rationale for developing Pim kinase inhibitors is 
to generate pan-inhibitors of all three family members, 
especially since triple knockout Pim kinase mice are 
viable.
Regulation of the Pim kinase family has focused 
mostly on Pim-1 and Pim-2, which are regulated by 
the  Jak/STAT-pathway  and  by  NfκB  [6,  10,  69-75]. 
Significantly less is known about how Pim-3 expression 
is regulated, albeit one report shows that Pim-3 can be 
regulated by the Ets family of transcription factors in NIH 
3T3 and human Ewing’s sarcoma cells [76]. Later studies 
showed that Pim-3 is activated by the Ets-1 transcription 
factor in pancreatic cancer cells [77]. Considering that 
Figure 4: Pimi induces cleavage of caspase-3 in G2/M and aneuploid cells but cell death is not blocked by pan-caspase 
inhibition. A) Eμ239 cells cultured in the presence of DMSO, Pim-ci or Pimi was harvested at indicated timepoints and divided into two 
subsets. One set was stained with propidium iodide (PI) for FACS analysis and the other set was cytospun onto glass slides, labeled with 
cleaved caspase-3 antibody and a FITC-secondary antibody and then subjected to immunofluorescense analysis as described in materials 
and methods. B) Pimi treated Eμ239 cells were fixed and intracellularly labeled with cleaved caspase-3 antibody and 7-amino actinomycin 
D (7AAD). Cells were analyzed by FACS for quantification of the cleaved caspase-3 signal related to each phase of the cell cycle. C) Cells 
co-treated for 48 hours with either DMSO, Pim-ci or Pimi and 20 μM of the pan-caspase inhibitor QVD-OPH were harvested and stained 
with propidium iodide (PI) and analyzed by FACS as well as cytospun onto glass slides, labeled with cleaved caspase-3 and analyzed by 
immunofluorescence.
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Pim kinases are constitutively active and protein levels are 
mainly regulated through transcriptional activation and 
proteosomal degradation [21, 78], our finding that Pim-3 
is regulated by Myc represents a significant addition to our 
understanding of Pim-3 regulation. It may also constitute 
an example of a feed-forward loop, since Pim-3 recently 
was shown to stabilize c-Myc [79]. This could offer an 
alternative explanation to why Myc’s transcriptional 
activity is decreased by Pimi-treatment in Eµ239 cells.
New targeted therapies are needed [80] and 
inhibition of Pim kinases has evoked a lot of interest 
but thus far no inhibitor has been granted approval for 
clinical use. Here we show that Myc-induced B cell 
lymphomas are sensitive to a new Pim kinase inhibitor 
generated at Abbott Laboratories, Pimi [63]. Whether or 
not Pim-3 is the sole target whose inhibition is the cause 
of the observed effect is not formally proven since RNAi 
against Pim3 yielded incomplete and thereby inconclusive 
knockdown data (not shown). Nevertheless, Pimi induces 
cell death that correlates with but may be independent 
of caspase-3 activation. The reason why we cannot 
exclude caspase-dependent death is that there is a debate 
whether or not complete caspase inhibition is achievable 
pharmacologically [81]. Here we observe a considerable 
reduction in cleaved caspase-3 with QVD-OPH but the 
remaining  amount  may  be  sufficient  to  trigger  death. 
If it is not classical caspase-dependent apoptosis then 
autophagy and/or programmed necrosis are candidate 
mechanisms. Indeed, autophagy was recently shown to 
be triggered by Pim-3 inhibition [79]. Given that Myc 
regulates metabolism [82] it would be plausible that 
interference with Myc’s transcriptional function would 
induce major changes in tumor cell metabolism that could 
result in apoptosis, autophagy and/or necrosis.
MAtErIAls And MEthods
reagents
Primary antibodies were obtained from Cell 
Signaling (Pim-3 (D17C9), pBad (Ser112, 40A9), 
Myc (D84C12), p4E-BP1 (Thr37/46), and Caspase-3 
(Asp175)), Santa Cruz (Pim-1(12H8), Pim-2(1D12), 
and Myc (N262)), Abcam (Pim-3) and Sigma (β-actin). 
Horseradish peroxidase-conjugated antibodies against 
mouse and rabbit antibodies were from GE Healthcare 
Life Sciences. The pan-caspase inhibitor Q-VD-OPH 
was obtained from Biovision. The Pim inhibitor, Pimi 
(2-Dimethylaminomethyl-8-(4-hydroxy-phenyl)-3H-
benzo[4,5]thieno[3,2-d]pyrimidin-4-one), and the non-
active control substance, Pim-ci, were obtained from 
Abbott Laboratories.
cell culture
NIH  3T3  fibroblasts  were  purchased  from 
American Type Culture Collection and where cultured 
in  Dulbecco´s  Modified  Eagle  Medium  supplemented 
with 10 % fetal calf serum FCS, 2 mM L-Glutamine, 1 
mM sodium pyruvate and 1 x antibiotic-antimycotic 
cocktail (penicillin/streptomycin/fungizone; Invitrogen). 
Human lymphoma cell lines P493-6 (a kind gift from Dr. 
Georg Bornkamm), human Burkitt Lymphoma cell lines; 
Akata, BJAB, Daudi, DG75, Louckes, P3HR1, Raji, 
Raji-EBNA6 and mouse lymphoma cell lines established 
from tumors arising in either λ-Myc or Eµ-Myc transgenic 
mice [29, 83] were cultivated in RPMI1640 medium 
supplemented with 10 % FCS, 2 mM L-glutamine, 50 µM 
β-mercaptoethanol, 0.1875 % sodium bicarbonate and 50 
µg/ml gentamicin. For Myc-ER experiments cells were 
grown in the presence or absence of 4-hydroxytamoxifen 
(4-HT) and/or cycloheximide (both from Sigma) for 4 h 
followed by RNA harvest and analysis.
cell cycle and apoptosis analysis
For cell cycle analysis, suspension cells were 
harvested by centrifugation after which the pellet was 
dissolved in Vindelöv´s solution (10 mM Tris, 10 mM 
NaCl, 75 µM propidium iodide, 0.1% Igepal and 700 units/
liter RNase adjusted to pH 8.0) to a final cell concentration 
of 1*105 - 1*106 c/ml. The cells were then analyzed in a 
FACScalibur flow cytometer (BD Biosciences) plotting 
cell cycle distribution in linear mode in the FL3 channel 
on the x-axis. Apoptotic cells were analyzed as having 
less than a diploid genome and depicted as sub-G1 cells 
in a logarithmic FL-2 channel. For cleaved caspase-3 
analysis, cells were fixed in 3% paraformaldehyde-PBS 
and permeabilized in ice-cold 90% methanol. Incubation 
with primary antibody against cleaved caspase-3 (Cell 
signaling) was performed overnight and was followed 
by incubation with a FITC-conjugated secondary 
antibody (Dako) for 1 h. Cells were then stained with 
7-aminoactinomycin D (7AAD; Sigma) and analyzed by 
FACS  analysis  on  a  FACScalibur  flow  cytometer  (BD 
Biosciences) using the FL1 (cleaved caspase-3) and FL2 
(7-AAD) channels.
Protein extraction and western blotting
Cells and harvested lymphomas were snapfrozen 
in  liquid  nitrogen  and  stored  at  -80  ̊C  until  further 
processing. Lymphomas were crushed in liquid nitrogen 
before addition of Tween-20 lysis buffer (50 mM Hepes, 
pH 7.5 /150 mM NaCl /1 mM EDTA/2.5 mM EGTA/0.1% 
Tween-20/ 1 mM phenylmethylsulfonyl fluoride/10mM 
β-glycerophosphate/1mM  NaF/  0.1mM  NaVO4 
supplemented with Minicomplete protease inhibitor 
cocktail tablets (Roche)) followed by sonication at 3 x 7sec 
pulses in a Soniprep 150 MSE, 20% power. Cell debris Oncotarget 2011; 2:  448 - 460 456 www.impactjournals.com/oncotarget
was pelleted by centrifugation at 1500 rpm (5 minutes, 4 
̊C) and supernatant was transferred to a fresh tube. Protein 
concentration was determined using the Bio-Rad protein 
determination kit. 50 μg of protein samples were separated 
on SDS-PAGE gels and transferred to nitrocellulose 
membranes (Schleicher-Schuell) activated in deionized 
water. Membranes were stained with Ponceau S Red dye 
to visualize equal loading and all subsequent steps were 
carried out in TBS-Tween (10 mM Tris-HCl, pH 7.6, 
150 mM NaCl and 0.05% Tween-20) either containing 
5% milk (blocking and antibody incubations) or 2 % 
BSA  (phosphospecific  antibody  incubations). Antibody 
binding was visualized by enhanced chemiluminescence 
using the SuperSignal West Dura or Pico reagents from 
Pierce and either an X-ray film or a LAS4000 imaging 
system (Fujifilm Lifescience).
rnA preparation and analysis
RNA was isolated using Trizol reagent (Invitrogen) 
or the NucleoSpin RNA II kit (Macherey-Nagel). Synthesis 
of  cDNA  was  made  with  iScript  first  strand  synthesis 
kit (Bio-Rad) on 1 μg RNA. Quantitative PCR (qPCR) 
was performed using the KAPA SYBR FAST qPCR Kit 
(Kapa Biosystems), cDNA and primers directed against 
Pim1, Pim2, Pim3, Srm, Myc, Amd1, Aurkb, Cad, Shmt1, 
Shmt2 or Ub (Ubiquitin)  on an iCycler iQ5 real-time 
PCR machine (Bio-Rad). Relative mRNA levels were 
calculated using the ∆∆CTmethod. Primer sequences are 
available on request.
chromatin immunoprecipitation (chIP)
P493-6 cells were grown in the presence of 0.1 ug/
ml tetracycline (Myc off) for 72 hours after which they 
were cleared of dead cells by centrifugation on a Ficoll 
(GE healthcare) gradient. One culture was continuously 
cultured in the presence of tetracycline (Myc off) whereas 
the other culture was grown in media only (Myc on). 
After 8 hours aliquots from each culture were taken 
for protein and mRNA analysis and the rest of cells 
(approximately 30 *10 6 cells) where cross-linked using 1 
% formaldehyde for 10 minutes. λ820 cells were expanded 
in normal media to correct cell density and were then 
cross-linked and handled as described before. The ChIP 
protocol was performed according to the manufacturer’s 
instructions (SimpleChIP enzymatic chromatin IP kit, 
Cell Signaling). Immunoprecipitations was performed 
using  Myc  antibodies  (λ820  cells;  D84C12,  Cell 
Signaling, P493-6 cells; N262, SantaCruz). qPCR was 
run on immunoprecipitated and control chromatin using 
primers against E-boxes in the mouse and human Pim-
3 gene. Control primers were designed against a region 
outside the Pim3 gene. A 1:50 volume of chromatin 
was processed without antibody and used as total input 
control for quantitative PCR. Percentage total chromatin 
immunoprecipitated was calculated using the equation 
% total = 2 (Ct input - Ct ChIP) x % input used for chromatin 
immunoprecipitation (ChIP). As positive controls for 
Myc transcriptional regulation, primers directed against 
the established Myc target genes Srm and Odc were used 
in the ChIP assay on λ820 cells, whereas primers against 
CCND2 were used for P493-6 cells. Sequences for primers 
are available on request.
Immunofluorescence and immunohistochemistry
Following treatment cells were harvested by cytospin 
onto glass slides. The cells were fixed and permeabilized 
with a PBS solution containing 4% paraformaldehyde 
and 0.2% Triton X-100 for 20 minutes and then washed 
in PBS and blocking solution (5% FCS in PBS). After 1 
hour of blocking, primary Caspase-3 antibody in blocking 
solution was added, and the slides were incubated 
overnight at 4°C in a moisture chamber. The cells were 
washed and incubated with a fluorescein isothiocyanate 
(FITC)–conjugated secondary antibody and subsequently 
stained with Hoechst and mounted. The slides were 
analyzed by fluorescence microscopy.
For  immunohistochemistry,  2-μm  sections  of 
lymphoma paraffin blocks were deparaffinized. Antigen 
retrieval was performed by pressure cooking in citrate 
buffer (pH6) for 7min. Primary antibodies against Pim-
3 (Abcam) were incubated overnight at 4°C. Antibody 
detection was performed using the DAKO REALTM 
detection kit (DAKO) according to the manufacturer’s 
protocol.
[3h]-thymidine incorporation
Cells were cultured in 96-well plates for 48 h in the 
presence of either DMSO or various concentrations of 
Pimi. The last 2 h of incubation, 20 μCi of [3H]-thymidine 
(Amersham)/ml media was added and the cells were 
harvested by a semiautomatic cell harvester (Inotech 
CH-5605 Dottikon). [3H]-thymidine incorporation 
was measured using a liquid scintillation counter 
(PerkinElmer). 
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